Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.41 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680823 | 0.83 | LMNA (0.57) | MEN1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2321667 | 0.83 | FFAR1 (0.48) | HTR2CMETAP2MEN1CYP1A2CYP3A4 | |
| SCHEMBL6690772 | 0.81 | HTT (0.57) | HTR2CMETAP2MEN1CYP1A2CYP3A4 | |
| SCHEMBL18347844 | 0.76 | HTR2C (0.42) | HTR2CMETAP2MEN1CYP1A2CYP3A4 | |
| N-Benzylaniline SCHEMBL7840 | 0.74 | HTT (0.71) | MEN1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL22628164 | 0.74 | HTT (0.71) | MEN1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15463279 | 0.74 | METAP2 (0.62) | HTR2CMETAP2HTTFFAR1PTPN1 | |
| SCHEMBL28855181 | 0.74 | FFAR1 (0.53) | HTR2CMETAP2MEN1KMT2AHTT | |
| SCHEMBL14662573 | 0.74 | MAPT (0.40) | MEN1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14661726 | 0.74 | MAPT (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703961-B2 | Thiazole derivatives for the treatment of diseases such as cancer | MERCK PATENT GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| EP-2513071-A1 | THIAZOLE DERIVATIVES FOR TREATING DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252759-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKER HAFTING (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011072779-A1 | THIAZOLE DERIVATIVES FOR TREATING DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252759-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | RET, IGF1R, JAK2 | HTR2C 3405/4885METAP2 3349/4885MEN1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.